Opus Genetics, Inc. (IRD) SEC filings

IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30483% above fair value

$4.06−0.25 (-5.80%)

Close on Nov 12, 2026Market cap $337.78MP/E –Yield –

SEC filings

40 of Opus Genetics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Nov 10, 2026	Nov 10, 2026	SEC EDGAR
Current report	8-K	Oct 19, 2026	Oct 21, 2026	SEC EDGAR
Current report	8-K	Oct 14, 2026	Oct 15, 2026	SEC EDGAR
Current report	8-K	Sep 11, 2026	Sep 11, 2026	SEC EDGAR
Current report	8-K	Sep 9, 2026	Sep 9, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Aug 6, 2026	Aug 6, 2026	SEC EDGAR
Current report	8-K	Jun 16, 2026	Jun 16, 2026	SEC EDGAR
Current report	8-K	Jun 16, 2026	Jun 16, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	May 12, 2026	May 12, 2026	SEC EDGAR
Current report	8-K	Apr 21, 2026	Apr 24, 2026	SEC EDGAR
Current report	8-K	Apr 20, 2026	Apr 22, 2026	SEC EDGAR
Current report	8-K	Apr 1, 2026	Apr 7, 2026	SEC EDGAR
Current report	8-K	Apr 2, 2026	Apr 7, 2026	SEC EDGAR
Proxy statement	DEF 14A	Apr 20, 2026	Mar 23, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 12, 2026	SEC EDGAR
Current report	8-K	Mar 10, 2026	Mar 10, 2026	SEC EDGAR
Current report	8-K	Feb 13, 2026	Feb 19, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Jan 8, 2026	Jan 8, 2026	SEC EDGAR
Current report	8-K	Dec 17, 2025	Dec 19, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 12, 2025	Nov 12, 2025	SEC EDGAR
Current report	8-K	Nov 5, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Nov 6, 2025	Nov 6, 2025	SEC EDGAR
Current report	8-K	Sep 30, 2025	Sep 30, 2025	SEC EDGAR
Current report	8-K	Aug 29, 2025	Sep 2, 2025	SEC EDGAR
Current report	8-K	Aug 25, 2025	Aug 25, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 13, 2025	SEC EDGAR
Current report	8-K	Aug 13, 2025	Aug 13, 2025	SEC EDGAR
Current report	8-K	Jul 22, 2025	Jul 23, 2025	SEC EDGAR
Current report	8-K	Jun 26, 2025	Jun 26, 2025	SEC EDGAR
Current report	8-K	Jun 25, 2025	Jun 25, 2025	SEC EDGAR
Current report	8-K	Jun 23, 2025	Jun 23, 2025	SEC EDGAR
Current report	8-K	Jun 13, 2025	Jun 20, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 15, 2025	SEC EDGAR
Current report	8-K	May 15, 2025	May 15, 2025	SEC EDGAR
Current report	8-K	Apr 30, 2025	May 1, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Opus Genetics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-4 reverse split on Nov 6, 2020
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IRD.

Compare: IRD vs TRDA · IRD vs PTN · IRD vs PRAX · IRD vs QURE · IRD vs XENE

Revenue growth-45.9% · median -93.5%

Operating margin-777.7% · median -2652.8%

Net margin-1726.7% · median -2606.4%

Company	Revenue	Growth
QURE	$20.17M	+28.0%
IRD	$7.91M	-45.9%
TRDA	$3.98M	-93.5%
PTN	–	–
PRAX	–	–
XENE	$0	-100.0%

Company

Next earnings (est.): Mar 9, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 27
Held by institutions: 72.8%
Auditor: Ernst & Young LLP
SEC CIK: 1228627

Advertisement
300 × 250

See a number that looks wrong?